BAT6005 / Bio-Thera Solutions - LARVOL DELTA

Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Bio-Thera Solutions | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Sep 2024

Trial completion • Trial completion date • Oncology • Solid Tumor

Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bio-Thera Solutions | Trial primary completion date: Dec 2022 ➔ Dec 2023

Metastases • Trial primary completion date • Oncology • Solid Tumor

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT (Businesswire) - "Bio-Thera Solutions, Ltd...announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers....The Phase 1, multicenter, open-label, dose-escalation clinical trial of BAT6005 is designed to assess the safety and tolerability of BAT6005 as a single agent. The study is expected to enroll subjects with advanced solid tumor."

Trial status • Oncology • Solid Tumor

Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Bio-Thera Solutions; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Bio-Thera Solutions

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • TIGIT

Bio-Thera’s TIGIT mAb BAT6005 nodded for trials in China (GBI Health) - "China-based Bio-Thera Solutions Ltd (SHA.688177) announced receiving the green light from the National Medical Products Administration (NMPA) to initiate a clinical study for its novel cancer drug BAT6005. BAT6005 is an IgG1 subtype TIGIT monoclonal antibody (mAb) with normal Fc effector function, set to enter development as a cancer therapy."

New trial • Oncology